Clinical Trial Update: Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating repeat dosing of SB-728mR-T after cyclophosphamide conditioning in HIV-infected individuals on HAART has completed with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• SB-728mR-T

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Human Immunodeficiency Virus (HIV) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-09